Objective: The aim of this study was to determine the incidence of asymptomatic, histologically proven prostatitis in men with symptoms of benign prostate hyperplasia and to observe the correlation between asymptomatic prostatitis and prostate specific antigen (PSA) density.
Introduction: The incidence of type IV prostatitis is unknown. There is a tendency to correlate the presence of inflammatory prostatitis with an elevation of PSA.
Materials And Methods: From August 2000 to January 2006, 183 patients who underwent surgical treatment for benign prostate hyperplasia as a result of obstructive or irritative symptoms were prospectively studied. In accordance with the histology findings, these patients were divided into two groups: group I included patients with the presence of histological prostatitis and group II included patients with the absence of histological prostatitis. The mean PSA densities were compared.
Results: Histological evidence of prostatitis was observed in 145 patients. In this group, the mean PSA density was 0.136 +/- 0.095. In 38 cases, there was no evidence of inflammation upon histological examination of the surgical samples. In these 38 cases, the mean PSA density was 0.126 +/- 0.129. No statistically significant differences were detected between the two groups; the p-value is 0.124.
Conclusion: Abnormal PSA density should not be attributed to the inflammatory prostatitis process.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780520 | PMC |
| http://dx.doi.org/10.1590/S1807-59322009001100003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the Diagnostic Accuracy of MRI-Derived Prostate-Specific Antigen (PSA) Density in Prostate Cancer Detection and its Association With Tumor Aggressiveness.
Cureus
November 2024
Department of Urology, Sligo University Hospital, Sligo, IRL.
Introduction Prostate-specific antigen density (PSAD), calculated by dividing serum PSA levels by prostate volume, offers greater specificity and accuracy than serum PSA alone in detecting prostate cancer (PCa). This study aimed to evaluate the diagnostic performance of PSAD in PCa detection across different PSA levels and its correlation with Gleason scores. Methods This retrospective, single-center study reviewed data from 154 patients with suspected PCa who underwent prostate MRI between July 2021 and July 2023.
View Article and Find Full Text PDFPredictive model for PSA persistence after radical prostatectomy using machine learning algorithms.
Front Oncol
December 2024
Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Objective: To evaluate the efficacy of a machine learning model for predicting prostate-specific antigen (PSA) persistence after radical prostatectomy (RP).
Methods: Data from 470 patients who underwent RP at the Affiliated Hospital of Qingdao University from January 2018 to June 2021 were retrospectively analyzed. Ten risk factors, including age, body mass index (BMI), preoperative PSA, biopsy Gleason score, total prostate specific antigen density (PSAD), clinical tumor stage, clinical lymph node status, seminal vesicle invasion, capsular invasion and positive surgical margin, were included in the analysis.
PI-RADS in Predicting csPCa: A Comparison Between Academic and Nonacademic Centers.
Prostate
December 2024
Urology Unit, Department of Medical, Oral and Biotechnological Sciences, 'G. d'Annunzio University', Chieti, Italy.
Introduction: The introduction of multiparametric prostate magnetic resonance imaging (mpMRI) has revolutionized prostate cancer (PCa) diagnosis, enhancing the localization of clinically significant prostate cancer (csPCa) and guiding targeted biopsies. However, significant disparities in the execution, interpretation, and reporting of prostate MRI examinations across centers necessitate greater standardization and accuracy. This study compares the diagnostic efficacy of mpMRI from academic and nonacademic centers in detecting csPCa and identifies factors associated with csPCa detection.
View Article and Find Full Text PDFIs there a comparable Mp-MRI for incidental prostate uptake on 18 F-FDG PET/CT?
World J Surg Oncol
December 2024
Department of Urology, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey.
Purpose: Although 18 F-FDG-PET/CT is helpful in defining many types of cancer, localized prostate cancer should not be treated with this technique. This study describes the use of multi-parametric MRI (mpMRI) to characterize incidental 18 F-FDG uptake in the prostate.
Methods And Materials: While 18 F-FDG-PET/CT is useful for characterizing a variety of cancers, it is not advised for prostate cancer that is localized.
Cancer detection in patients with prostate-specific antigen levels within the grey zone: can synthetic magnetic resonance imaging aid in the differentiation between prostate cancer and noncancerous lesions?
Quant Imaging Med Surg
December 2024
Department of Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Background: The detection of prostate cancer (PCa) via conventional magnetic resonance imaging (MRI) in patients with prostate-specific antigen (PSA) levels within the grey zone remains challenging. Whether synthetic MRI can provide supplementary benefits for the accurate diagnosis of PCa in this specific population is still unknown. This study aims to investigate the diagnostic performance of synthetic MRI for differentiating PCa lesions from noncancerous lesions in patients with PSA levels within the grey zone (4-10 ng/mL).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!